Sometimes you have this project idea in your mind that seems so simple and straightforward, and which feels just so right that you have to roll with it. Then, years later you stumble across the sad ...
After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
New research suggests pain is not a simple signal of injury but a process that unfolds across nerves, spinal cord, and brain. Scientists are now targeting earlier points in that pathway, before pain ...
Vector Security has provided intelligent security solutions for more than 50 years. Headquartered in Pittsburgh, the company offers a full suite of electronic security services for residential, ...
Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study. Comparison of checkpoint inhibitor treatment-related cutaneous adverse ...
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
SPG Simon Property Group, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results